Bone distribution study of anti leprotic drug clofazimine in rat bone marrow cells by a sensitive reverse phase liquid chromatography method

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 960, Issue , 2014, Pages 82-86

  Srikanth, Cheruvu Hanumanth ^a   Joshi, Pankaj ^a   Bikkasani, Anil Kumar ^a   Porwal, Konica ^a   Gayen, Jiaur R ^a,b  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Bone marrow distribution; Clastogenic effect; Clofazimine; Liquid liquid extraction; Rat bone marrow cells; Rat plasma; RP HPLC

Indexed keywords

BODY FLUIDS; BONE; CHROMATOGRAPHY; COUPLINGS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; PHARMACOKINETICS; RATS;

BONE MARROW; CLASTOGENIC EFFECT; CLOFAZIMINE; LIQUID-LIQUID EXTRACTION; RAT BONE MARROW CELLS; RAT PLASMA; RP-HPLC;

CELLS;

CLOFAZIMINE; LEPROSTATIC AGENT;

ACCURACY; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HUMAN TISSUE; LIQUID LIQUID EXTRACTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BLOOD; CHEMISTRY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; PROCEDURES; REPRODUCIBILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT; STATISTICAL MODEL; TISSUE DISTRIBUTION;

ANIMALS; BONE MARROW CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; CLOFAZIMINE; DRUG STABILITY; LEPROSTATIC AGENTS; LINEAR MODELS; LIQUID-LIQUID EXTRACTION; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84899735435     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2014.04.022     Document Type: Article

References (21)

1. Sahu K., Das R. Food Chem. Toxicol. 1994, 32:911-915.
2. Krishna D.R., Mamidi R.N., Hofmann U., Prabhakar C.M. Arzneimittelforschung 1997, 47:303-306.
3. Mackey J.P., Barnes J. Br. J. Dermatol. 1974, 91:93-96.
4. Mamidi N., Rajasekhar A., Prabhakar M., Krishna D. Arzneim.-Forsch. 1995, 45:1029.
5. Lu Y., Zheng M., Wang B., Zhao W., Fu L., Li P., Liang B., Chu N. Zhonghua jie he he hu xi za zhi=Zhonghua jiehe he huxi zazhi=Chin. J. Tuberc. Respir. Dis. 2009, 32:694.
6. Borner K., Hartwig H., Leitzke S., Hahn H., Müller R.H., Ehlers S. Int. J. Antimicrob. Agents 1999, 11:75-79.
7. Jadhav M., Sathe A., Deore S., Patil P., Joshi N. Indian J. Pathol. Microbiol. 2004, 47:281.
8. Venkatesan K., Deo N., Gupta U.D. Arzneimittelforschung 2007, 57:472-474.
9. Das R., Roy B. Mutat. Res./Genet. Toxicol. 1990, 241:161-168.
10. Dash B., Roy B., Das R. In vivo (Athens, Greece) 1991, 5:69.
11. Roy B., Das R. Mutat. Res./Genet. Toxicol. 1990, 241:169-173.
12. Holdiness M.R. Clin. Pharmacokinet. 1989, 16:74-85.
13. Gidoh M., Tsutsumi S., Takitani S. J. Chromatogr. 1981, 223:379-392.
14. Peters J.H., Hamme K.J., Gordon G.R. J. Chromatogr. 1982, 229:503-508.
15. Queiroz R.H., Pereira R.C., Gotardo M.A., Cordeiro D.S., Melchior E. J. Anal. Toxicol. 2003, 27:377-380.
16. O'connor R., O'sullivan J., O'kennedy R. Drug Metab. Rev. 1995, 27:591-614.
17. Krishnan T.R., Abraham I. Int. J. Lepr. Other Mycobact. Dis. 1992, 60:549-555.
18. U.S.-FDA, Rockville, MD: CDER, Report to the Nation Improving Public Health Through Human Drugs (2001).
19. Joshi P., Rao S., Singh M., Vig N., Singh A.K., Rajawat N.S., Gupta A. Anal. Methods 2013, 5:7014-7021.
20. Hasnain M.S., Rao S., Singh M.K., Vig N., Gupta A., Ansari A., Sen P., Joshi P., Ansari S.A. Analyst 2013, 138:1581-1588.
21. Srikanth C.H., Chaira T., Sampathi S., Bambal B.S.V.R.B. Analyst 2013, 138:6106-6116.